Antiviral activity and in vitro mutation development pathways of MK-6186, a novel nonnucleoside reverse transcriptase inhibitor

Antimicrobial Agents and Chemotherapy

Volumn 56, Issue 6, 2012, Pages 3324-3335

  Lu, Meiqing ^a   Felock, Peter J ^a   Munshi, Vandna ^a   Hrin, Renee C ^a   Wang, Ying Jie ^a,b   Yan, Youwei ^a   Munshi, Sanjeev ^a   McGaughey, Georgia B ^a   Gomez, Robert ^a   Anthony, Neville J ^a   Williams, Theresa M ^a   Grobler, Jay A ^a   Hazuda, Daria J ^a   McKenna, Philip M ^a   Miller, Michael D ^a   Lai, Ming Tain ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

^b ZHEJIANG UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; EFAVIRENZ; ETRAVIRINE; MK 6186; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; UNCLASSIFIED DRUG;

ANTIVIRAL ACTIVITY; ANTIVIRAL RESISTANCE; ANTIVIRAL SUSCEPTIBILITY; ARTICLE; DRUG EFFICACY; DRUG POTENCY; DRUG STRUCTURE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; IC 50; IN VITRO STUDY; NONHUMAN; PREVALENCE; PRIORITY JOURNAL; VIRUS CELL TRANSFORMATION; VIRUS ISOLATION; VIRUS MUTANT; VIRUS MUTATION; VIRUS REPLICATION; VIRUS STRAIN;

ANTI-HIV AGENTS; BENZOXAZINES; HIV REVERSE TRANSCRIPTASE; HIV-1; MUTATION; REVERSE TRANSCRIPTASE INHIBITORS;

EID: 84861179369     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00102-12     Document Type: Article

References (42)

1. Ambrose Z, Julias JG, Boyer PL, Kewalramani VN, Hughes SH. 2006. The level of reverse transcriptase (RT) in human immunodeficiency virus type 1 particles affects susceptibility to nonnucleoside RT inhibitors but not to lamivudine. J. Virol. 80:2578-2581. (Pubitemid 43271563)
2. Archer RH, et al. 2000. Mutants of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase resistant to nonnucleoside reverse transcriptase inhibitors demonstrate altered rates of RNase H cleavage that correlate with HIV-1 replication fitness in cell culture. J. Virol. 74:8390-8401. (Pubitemid 30666690)
3. Babic DZ, et al. 2006. Prevalence of antiretroviral drug resistance mutations and HIV-1 non-B subtypes in newly diagnosed drug-naive patients in Slovenia, 2000-2004. Virus Res. 118:156-163.
4. Bacheler L, et al. 2001. Genotypic correlates of phenotypic resistance to efavirenz in virus isolates from patients failing nonnucleoside reverse transcriptase inhibitor therapy. J. Virol. 75:4999-5008. (Pubitemid 32448520)
5. Brenner B, et al. 2003. A V106M mutation in HIV-1 clade C viruses exposed to efavirenz confers cross-resistance to non-nucleoside reverse transcriptase inhibitors. AIDS 17:F1-F5. (Pubitemid 36106291)
6. Caride E, et al. 2000. Drug-resistant reverse transcriptase genotyping and phenotyping of B and non-B subtypes (F and A) of human immunodeficiency virus type I found in Brazilian patients failing HAART. Virology 275:107-115.
7. Caride E, et al. 2001. Genotypic and phenotypic evidence of different drug-resistance mutation patterns between B and non-B subtype isolates of human immunodeficiency virus type 1 found in Brazilian patients failing HAART. Virus Genes 23:193-202. (Pubitemid 33020696)
8. Carr JK, et al. 1998. Full genome sequences of human immunodeficiency virus type 1 subtypes G and A/G intersubtype recombinants. Virology 247:22-31. (Pubitemid 28384022)
9. Castro HC, et al. 2006. HIV-1 reverse transcriptase: a therapeutical target in the spotlight. Curr. Med. Chem. 13:313-324.
10. Das K, et al. 2004. Roles of conformational and positional adaptability in structure-based design of TMC125-R165335 (etravirine) and related nonnucleoside reverse transcriptase inhibitors that are highly potent and effective against wild-type and drug-resistant HIV-1 variants. J. Med. Chem. 47:2550-2560. (Pubitemid 38580092)
11. Das K, Lewi PJ, Hughes SH, Arnold E. 2005. Crystallography and the design of anti-AIDS drugs: conformational flexibility and positional adaptability are important in the design of non-nucleoside HIV-1 reverse transcriptase inhibitors. Prog. Biophys. Mol. Biol. 88:209-231. (Pubitemid 39579659)
12. Delaugerre C, et al. 2001. Resistance profile and cross-resistance of HIV-1 among patients failing a non-nucleoside reverse transcriptase inhibitor-containing regimen. J. Med. Virol. 65:445-448. (Pubitemid 32959067)
13. Gazzard B, et al. 2006. British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy (2006). HIV Med. 7:487-503. (Pubitemid 44742349)
14. Gomez R, et al. 2011. Design and synthesis of conformationally constrained inhibitors of non-nucleoside reverse transcriptase. J. Med. Chem. 54:7920-7933.
15. Gotte M, Li X, Wainberg MA. 1999. HIV-1 reverse transcription: a brief overview focused on structure-function relationships among molecules involved in initiation of the reaction. Arch. Biochem. Biophys. 365:199-210. (Pubitemid 29391627)
16. Grossman Z, et al. 2004. Genetic variation at NNRTI resistance-associated positions in patients infected with HIV-1 subtype C. AIDS 18: 909-915. (Pubitemid 38553711)
17. Hammer SM, et al. 2006. Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society-U. S. A. panel. JAMA 296:827-843. (Pubitemid 44223106)
18. Harris ME, et al. 2003. A cluster of HIV type 1 subtype C sequences from Ethiopia, observed in full genome analysis, is not sustained in subgenomic regions. AIDS Res. Hum. Retrovir. 19:1125-1133. (Pubitemid 38037382)
19. Holguin A, Ramirez A, Rivas P, Soriano V. 2006. Efficacy of antiretroviral therapy in individuals infected with HIV-1 non-B subtypes. AIDS Rev. 8:98-107. (Pubitemid 44043558)
20. Hopkins AL, et al. 1996. Complexes of HIV-1 reverse transcriptase with inhibitors of the HEPT series reveal conformational changes relevant to the design of potent non-nucleoside inhibitors. J. Med. Chem. 39:1589-1600.
21. Javanbakht H, et al. 2010. In vitro resistance development for RO-0335, a novel diphenylether nonnucleoside reverse transcriptase inhibitor. Antiviral Res. 86:212-219.
22. Johnson LB, Saravolatz LD. 2009. Etravirine, a next-generation nonnucleoside reverse-transcriptase inhibitor. Clin. Infect. Dis. 48:1123-1128.
23. Kantor R, et al. 2005. Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: results of a global collaboration. PLoS Med. 2:e112.
24. Lai MT, et al. 2010. Distinct mutation pathways of non-subtype B HIV-1 during in vitro resistance selection with nonnucleoside reverse transcriptase inhibitors. Antimicrob. Agents Chemother. 54:4812-4824.
25. Lai MT, et al. 2009. Antiviral activity of MK-4965, a novel nonnucleoside reverse transcriptase inhibitor. Antimicrob. Agents Chemother. 53:2424-2431.
26. Martinez-Picado J, Martinez MA. 2008. HIV-1 reverse transcriptase inhibitor resistance mutations and fitness: a view from the clinic and ex vivo. Virus Res. 134:104-123.
27. Moore JP, Stevenson M. 2000. New targets for inhibitors of HIV-1 replication. Nat. Rev. Mol. Cell Biol. 1:40-49.
28. Munshi V, et al. 2008. Monitoring the development of non-nucleoside reverse transcriptase inhibitor-associated resistant HIV-1 using an electrochemiluminescence-based reverse transcriptase polymerase assay. Anal. Biochem. 374:121-132.
29. Palella FJ, et al. 1998. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N. Engl. J. Med. 338:853-860.
30. Petropoulos CJ, et al. 2000. A novel phenotypic drug susceptibility assay for human immunodeficiency virus type 1. Antimicrob. Agents Chemother. 44:920-928. (Pubitemid 30165271)
31. Sato A, et al. 2006. In vitro selection of mutations in human immunodeficiency virus type 1 reverse transcriptase that confer resistance to capravirine, a novel nonnucleoside reverse transcriptase inhibitor. Antiviral Res. 70:66-74.
32. Schneider MF, et al. 2005. Patterns of the hazard of death after AIDS through the evolution of antiretroviral therapy: 1984-2004. AIDS 19: 2009-2018. (Pubitemid 41669026)
33. Shafer RW, Schapiro JM. 2008. HIV-1 drug resistance mutations: an updated framework for the second decade of HAART. AIDS Rev. 10:67-84.
34. Shaw-Reid CA, et al. 2003. Inhibition of HIV-1 ribonuclease H by a novel diketo acid, 4-[5-(benzoylamino)thien-2-yl]-2,4-dioxobutanoic acid. J. Biol. Chem. 278:2777-2780. (Pubitemid 36801178)
35. Soriano V, de Mendoza C. 2002. Genetic mechanisms of resistance to NRTI and NNRTI. HIV Clin. Trials 3:237-248. (Pubitemid 34704872)
36. Spira S, Wainberg MA, Loemba H, Turner D, Brenner BG. 2003. Impact of clade diversity on HIV-1 virulence, antiretroviral drug sensitivity and drug resistance. J. Antimicrob. Chemother. 51:229-240. (Pubitemid 36231141)
37. Sweeney ZK, Klumpp K. 2008. Improving non-nucleoside reverse transcriptase inhibitors for first-line treatment of HIV infection: the development pipeline and recent clinical data. Curr. Opin. Drug Discov. Dev. 11:458-470. (Pubitemid 351950841)
38. Tachedjian G, Aronson HE, Goff SP. 2000. Analysis of mutations and suppressors affecting interactions between the subunits of the HIV type 1 reverse transcriptase. Proc. Natl. Acad. Sci. U. S. A. 97:6334-6339. (Pubitemid 30412714)
39. Takeb E, Kusagawa YS, Motomura K. 2004. Molecular epidemiology of HIV: tracking AIDS pandemic. Pediatr. Int. 46:236-244. (Pubitemid 38526626)
40. Vingerhoets J, et al. 2005. TMC125 displays a high genetic barrier to the development of resistance: evidence from in vitro selection experiments. J. Virol. 79:12773-12782. (Pubitemid 41433197)
41. Wang YJ, et al. 2010. Assessment of the susceptibility of mutant HIV-1 to antiviral agents. J. Virol. Methods 165:230-237.
42. Xu H, et al. 2009. Human immunodeficiency virus type 1 recombinant reverse transcriptase enzymes containing the G190A and Y181C resistance mutations remain sensitive to etravirine. Antimicrob. Agents Chemother. 53:4667-4672.